South Korea's LG Takes Shot At Vaccines Via In-licensing Deal With U.S. Novavax
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's LG Life Sciences said next year it will start building a production plant in Osong, south of the capital city of Seoul, to produce cell-culture influenza vaccines based on the virus-like particle technology in-licensed from Novavax of the U.S